Transcript PPT template

Raffaele,
living with epilepsy
Delivering to become
the next generation
biopharma leader
UCB
Corporate Presentation
June 2009
Disclaimer and safe harbour
2
This presentation includes “forward-looking statements” relating to UCB and Schwarz Pharma that are subject
to known and unknown risks and uncertainties, many of which are outside of UCB’s and Schwarz Pharma’s
control and are difficult to predict, that may cause actual results to differ materially from any future results
expressed or implied from the forward-looking statements. In this presentation, the words “anticipates,”
“believes,” “estimates,” “seeks,” “expects,” “plans,” “intends” and similar expressions, as they relate to UCB or
Schwarz Pharma, are intended to identify forward-looking statements. Important factors that could cause
actual results to differ materially from such expectations include, without limitation: the inability to obtain
necessary regulatory approvals or to obtain them on acceptable terms; the inability to integrate successfully
Schwarz Pharma within UCB or to realize synergies from such integration following the acquisition; costs
related to the acquisition of Schwarz Pharma; the economic environment of the industries in which UCB and
Schwarz Pharma operate; costs associated with research and development; changes in the prospects for
products in the pipeline or under development by UCB or Schwarz Pharma; dependence on the existing
management of UCB and Schwarz Pharma; changes or uncertainties in Belgian or German tax laws or the
administration of such laws; changes or uncertainties in the laws or regulations applicable to the markets in
which UCB and Schwarz Pharma operate. All written and oral forward-looking statements attributable to UCB
or Schwarz Pharma or persons acting on either of their behalf are expressly qualified in their entirety by the
cautionary statements above. Neither UCB nor Schwarz Pharma intend, or undertake any obligation, to
update these forward-looking statements.
the next generation biopharma leader June 2009
Forward-looking statements:
UCB
3
• To become the next generation biopharmaceutical leader
• To provide breakthrough innovation for patients suffering
from severe diseases
Therapeutic focus
• Central nervous system (CNS)
• Immunology
Foundation
• UCB = UCB Pharma + Celltech (2004) + Schwarz Pharma (2006)
• UCB = unique combination of large, antibody-based molecules and
small, chemically-derived molecules
the next generation biopharma leader June 2009
Vision
UCB
Our “road map”
4
Intense growth
Execution
Realise the commercial
potential of new products
Launch a new
generation of therapies
offering breakthrough
innovation to patients
with severe disease
• Launch
new products
• Invest in R&D
• SHAPE the organisation for the
future
• Prioritise products and markets
• Improve competitiveness and
profitability
2007
2010
... and beyond
the next generation biopharma leader June 2009
Breakthrough
2008
UCB continues on track
5
organisation and to increase focus on UCB core disease areas,
products and geographies
2008: three new molecular entities (NME’s) approved in the U.S.
2008/2009: major product launches - Vimpat®, Neupro®,
Cimzia® - ongoing and in preparation
In-line with financial guidance
the next generation biopharma leader June 2009
SHAPE: major steps taken to accelerate the transformation of the
2008
Financial highlights
6
Recurring EBITDA of € 733 million (-1%)
Net profit € 42 million (-74%) impacted by:
• Significant restructuring expenses and fixed asset impairment charges
related to the SHAPE programme
• Financial expenses related to purchase of minority Schwarz Pharma
shares
Adjusted1 net profit € 270 million (-7%)
1
Adjusted for after-tax impact of one-off items, contribution from
discontinued operations and inventory step-up
the next generation biopharma leader June 2009
Revenue of € 3 601 million in line with previous year
2008
7 regulatory approvals and 6 filings
7
• Cimzia®
Crohn's disease (U.S.) - launched
• Keppra® XR
Adjunctive therapy in epilepsy (U.S.) - launched
• Neupro®
Restless legs syndrome (EU) – launch expected H1 2009
• Toviaz®
Overactive bladder (U.S.) – licensed to Pfizer
• Vimpat®
Adjunctive therapy in epilepsy (EU) - launched
• Vimpat®
Adjunctive therapy in epilepsy (U.S.) - launch expected Q2 2009
• Xyzal®
Antihistamine oral solution (U.S.) - launched
Six filings
• Cimzia®
Rheumatoid arthritis (EU)
• Cimzia®
Rheumatoid arthritis (U.S.)
• Keppra®
Adjunctive therapy in epilepsy (infants and children1 – U.S.)
• Keppra®
Adjunctive therapy in epilepsy (infants and children1 – EU)
• Keppra®
Adjunctive therapy in epilepsy (Japan)
• Keppra® XR
Adjunctive therapy in epilepsy (U.S.)
1
For children aged from one month to under four years
the next generation biopharma leader June 2009
Seven regulatory approvals
2008
Most NME approvals in the U.S.
8
and one out of four Biologics License Applications (BLA) approved
3
2
1
2
3
4
3
WAT
SON
LABS
WYE
TH P
HAR
MS I
NC
UCB4
UCB
TI BO
TEC
.
ERA
P
N TH
SIRIO
HAR
M
REG
ENE
RO N
P
PRO
GEN
ICS
JANS
SEN
O
MED
SC
O MC
NEIL
ORT
H
NE
GLA
XOS
MI TH
KLI
GEN
ZYM
E
ING
ARE
GE H
EALT
HC
FER
R
EPIX
PHA
R MA
EISA
I
CEP
HALO
N
AMG
EN
ADO
LOR
0
ASTE
LLAS
BAY
ER H
LT HC
ARE
BIO V
AIL A
MER
ICAS
1
New Molecular Entity - Source: FDA website
Adolor and GlaxoSmithKline collaborated on Entereg
Progenics and Wyeth collaborated on Relistor
Toviaz® (Pfizer), Vimpat® (Schwarz Pharma) and Cimzia® are all
grouped under UCB - Toviaz® is officially listed on FDA site as
Pfizer. NDA filed by Schwarz Pharma and while approvable, was
transferred to Pfizer
the next generation biopharma leader June 2009
Three out of 24 NME1 approvals in 2008 for UCB
2008
4 + 1 new product launches
9
Launched in the U.S.
Adjunctive therapy in epilepsy
Launched in Germany and U.K.
Adjunctive therapy in epilepsy
Launched in the U.S.
Oral antihistamine solution
Launched in the U.S.
Toviaz®
Overactive bladder
Launched in the EU, by Pfizer
the next generation biopharma leader June 2009
Crohn's disease
Solid CNS & immunology pipeline
Key projects
10
Phase II
Phase III
Filed
CDP7851
bone loss disorders
CDP323
multiple sclerosis
Vimpat®
epilepsy
monotherapy - U.S.
Neupro®
adv. Parkinson's
disease - U.S1
CDP6038
autoimmune
diseases
epratuzumab
systemic lupus
erythematosus
Vimpat®
diabetic neuropathic
pain - EU + U.S.
Neupro®
restless legs
syndrome - U.S.1
brivaracetam
epilepsy
Cimzia®
rheumatoid arthritis
- EU
Approved
Neupro®
restless legs
syndrome – EU2
Keppra® XR
epilepsy
monotherapy - U.S.
Cimzia®
Crohn's disease EU
CNS
Immunology
1
2
Neupro® Complete Response Letter (December 2008)
CHMP recommends lifting of treatment restrictions for Neupro® in
Europe (May 2009)
the next generation biopharma leader June 2009
Phase I
CNS
Expansion in our core area
11
Vimpat®
brivaracetam
Parkinson's disease (PD)
Neupro®
Restless legs syndrome (RLS)
Neupro®
Diabetic neuropathic pain (DNP)
Vimpat®
Multiple sclerosis (MS)
CDP323
the next generation biopharma leader June 2009
Epilepsy
Epilepsy
Major unmet medical need
12
50%
25-30%
20-25%
Controlled on 1st monotherapy
Uncontrolled despite 2-3 AEDs
"Controlled" on more than 1 AED
Patients with only one seizure/month report significant impact on their
social life, ability to work and standard of living
No new AED’s1 approved in over 5 years (U.S.)
Few future treatments expected, particularly with a novel mode of action
There is a strong need for a new treatment option
1
Antiepileptic drug
the next generation biopharma leader June 2009
High unmet medical need in ~1/3 of treated epilepsy patients
Vimpat® in epilepsy – a new treatment option
Monotherapy Phase III programme ongoing
13
the next generation biopharma leader June 2009
Novel dual mode of action
Easy to use
• No clinically significant drug-drug interactions
• Multiple formulations: tablets, syrup, IV
Monotherapy Phase III trial in the U.S. ongoing
• U.S. market = 70% of monotherapy market
Lakeisha,
living with epilepsy
Phase I
Vimpat® (lacosamide)
Epilepsy – Adjunctive therapy (EU)
Vimpat® (lacosamide)
Epilepsy – Adjunctive therapy (U.S.)
Vimpat® (lacosamide)
Epilepsy – Monotherapy (U.S.)
Phase II
Phase III
Filed
Approved
Launched
August
2007
September
2008
September
2008
November
2007
October
2008
May
2009
Results
expected
Q2 2011
Vimpat® has been designated as a Schedule V controlled
substance by U.S. regulators.
Brivaracetam in epilepsy
Phase III programme ongoing
14
the next generation biopharma leader June 2009
Broader mechanism of action than Keppra®
Population includes patients not controlled with Keppra®
Phase III top line results (April 2009):
• Study N01253 met its primary efficacy endpoint
• Study N01252 did not meet its primary efficacy endpoint
• Study N01254 confirmed brivaracetam was well tolerated
• Further analysis will be conducted
• Regulatory authorities will be consulted to determine next steps
Path forward update expected by year end
Phase I
Brivaracetam
Epilepsy adjunctive therapy
Phase II
Phase III
April
2009
Filed
Approved
Launched
Neupro® in Parkinson's disease
Getting closer to make it available for new patients in Europe
15
the next generation biopharma leader June 2009
Deviation from product approved specification
Restriction on promotion (June 2008)
•
To manage potential shortages: existing patients only
Full cold storage and distribution chain implemented
(September 2008)
CHMP1 positive opinion (May 2009) recommending:
•
Lifting of treatment restrictions for Neupro® in Europe
•
Allowing Neupro® to be available to all patients with Parkinson’s
disease
Phase I
Phase II
Terry,
living with Parkinson’s disease
Phase III
Filed
Approved
Launched
Neupro® (rotigotine)
Early stage Parkinson's disease (EU)
February
2006
March
2006
Neupro® (rotigotine)
Advanced Parkinson's disease (EU)
January
2007
January
2007
1
CHMP: EMEA's Committee for Medicinal Products for Human Use
Neupro® in Parkinson's disease
Working to make it available for new patients in the U.S.
16
the next generation biopharma leader June 2009
Deviation from product approved specification
Product recall (March 2008)
•
Out-of-stock situation
FDA Complete Response Letter (December 2008)
•
“Substantial evidence of effectiveness in advanced Parkinson’s
disease and restless legs syndrome (RLS)”
•
Dialogue ongoing with the FDA to bring Neupro® back to U.S.
patients
Wolfgang,
living with Parkinson’s disease
Phase I
Neupro® (rotigotine)
Early stage Parkinson's disease (U.S.)
Neupro® (rotigotine)
Advanced Parkinson's disease (U.S.)
Phase II
Phase III
Filed
December
2007
Approved
Launched
May
2007
July
2007
Neupro® in restless legs syndrome
Increased awareness of an unrecognised disease
17
the next generation biopharma leader June 2009
Demonstrated efficacy and well tolerated
Consistent results within comprehensive clinical program
•
Improved sleep and reduced daytime tiredness
•
Potential first line treatment EU approval (September 2008)
FDA Complete Response Letter (December 2008)
•
“Substantial evidence of effectiveness in advanced Parkinson’s
disease and restless legs syndrome (RLS)”
Sten,
living with restless legs syndrome
CHMP positive opinion (May 2009)
•
Recommends allowing Neupro® to be launched for the treatment
of moderate to severe RLS
Phase I
Neupro® (rotigotine)
Restless legs syndrome (EU)
Neupro® (rotigotine)
Restless legs syndrome (U.S.)
Phase II
Phase III
Filed
Approved
September
2008
December
2007
Launched
Vimpat® in diabetic neuropathic pain
Path forward to be elaborated
18
•
Demonstrated sustained efficacy and good tolerability
•
No drug-drug / food interactions, no weight gain
•
New mode of action
FDA Not Approvable Letter (July 2008)
Withdrawal of MAA1 in EU (September 2008)
Optimise design of future studies to meet conservative
statistical requirements and then discuss with authorities
Frieda,
living with diabetic neuropathic pain
UCB decision expected H2 2009
Phase I
Vimpat® (lacosamide)
Diabetic neuropathic pain (EU)
Vimpat® (lacosamide)
Diabetic neuropathic pain (U.S.)
1
Phase II
Phase III
Marketing Authorisation Application
Filed
Approved
Launched
the next generation biopharma leader June 2009
Promising drug for a large unmet medical need
CDP323 in multiple sclerosis
Oral administration
19
the next generation biopharma leader June 2009
Potent and orally active small molecule antagonist of alpha 4-integrin
Successful collaboration with Biogen IDEC
Phase II programme ongoing
Phase I
CDP323
Multiple sclerosis
Phase II
Results
expected
2010
Phase III
Filed
Approved
Launched
Immunology
20
Cimzia®
Rheumatoid arthritis (RA)
Cimzia®
Bone loss disorders
CDP7851
Systemic lupus erythematosus (SLE)
epratuzumab
the next generation biopharma leader June 2009
Crohn's disease (CD)
Cimzia® in rheumatoid arthritis
Only PEGylated Fc-free anti-TNF
21
the next generation biopharma leader June 2009
Approved and launched in the U.S.
Filed with European authorities (July 2008)
• Review pending
Alison,
living with rheumatoid arthritis
Phase I
Cimzia® (certolizumab pegol)
Rheumatoid arthritis (U.S.)
Cimzia® (certolizumab pegol)
Rheumatoid arthritis (EU)
Phase II
Phase III
Filed
Approved
Launched
February
2008
May
2009
May
2009
July
2008
CDP7851 in bone loss disorders
Novel therapy with strong potential
22
Study of naturally occurring human
disorder leads to a potential new
drug therapy
• Antibody to sclerostin potentially treating bone loss
disorders, incl. osteoporosis
Collaborative project with Amgen
Phase I: first positive results
• UCB and Amgen are encouraged by the first-in-
human data and are currently planning the future
development program
Normal
Phase I
CDP7851 (anti-sclerostin)
Bone loss disorders
Results
expected H2
2009
Phase II
Phase III
Sclerosteosis
Filed
Approved
Launched
the next generation biopharma leader June 2009
Development of novel anabolic therapy
Epratuzumab in systemic lupus erythematosus (SLE)
Phase IIb study ongoing
23
the next generation biopharma leader June 2009
Analyses of recently closed clinical trials suggest a favourable efficacy
and tolerability profile
Phase IIb dose ranging study ongoing
• Number of randomized patients: 210
• Arms/doses: 6 arms dose range (from 150 – 3 600 mg/cycle)
• Duration: 3 months treatment phase
• Primary endpoint: reduction disease activity
• Population: patients with moderate/severe activity
Phase I
Epratuzumab
Systemic lupus erythematosus
Phase II
Results
expected
Q3 2009
Phase III
Filed
Approved
Launched
Solid CNS & immunology pipeline
Key projects
24
Phase II
Phase III
Filed
CDP7851
bone loss disorders
CDP323
multiple sclerosis
Vimpat®
epilepsy
monotherapy - U.S.
Neupro®
adv. Parkinson's
disease - U.S1
CDP6038
autoimmune
diseases
epratuzumab
systemic lupus
erythematosus
Vimpat®
diabetic neuropathic
pain - EU + U.S.
Neupro®
restless legs
syndrome - U.S.1
brivaracetam
epilepsy
Cimzia®
rheumatoid arthritis
- EU
Approved
Neupro®
restless legs
syndrome – EU2
Keppra® XR
epilepsy
monotherapy - U.S.
Cimzia®
Crohn's disease EU
CNS
Immunology
1
2
Neupro® Complete Response Letter (December 2008)
CHMP recommends lifting of treatment restrictions for Neupro® in
Europe (May 2009)
the next generation biopharma leader June 2009
Phase I
SHAPE
Transformation and focus
25
Focus on core products and geographies
Drive for breakthrough innovation for patients with
severe disease
Simplify the organisation
Improve competitiveness and profitability
the next generation biopharma leader June 2009
Focus on CNS and immunology
SHAPE
Achievements so far
26
• Workforce already reduced by 15%
Resources reallocated to core assets
Pre-clinical oncology portfolio incubated with Wilex (January 2009)
• UCB retains buy-back options
Non-strategic emerging markets divested to GSK (January 2009)
Equasym™ IR/XL and Somatostatine-UCB™ divested (February 2009)
UCB NewMedicines™
• Drug discovery to proof-of-concept organisation
• New external focus reinforced through new partnerships with academic
collaborations
• CDP6038 (IL-6) for auto-immune diseases entered Phase I (December 2008)
the next generation biopharma leader June 2009
Organisation simplified and focused
UCB priorities for 2009
27
Continue delivery of late stage pipeline
SHAPE:
• Maximise core assets, optimise non-core assets
• Fully implement new organisational and geographical footprint
Prepare for ‘Breakthrough Phase’ by building pipeline and
strengthening new biopharma capabilities
Foster patient centricity as a key driver of performance
the next generation biopharma leader June 2009
Successfully launch Vimpat®, Neupro®, Cimzia®
2009 financial outlook
28
• Full generic competition to Keppra® in the U.S for the whole year
• Partially compensated by newly launched products
Recurring EBITDA target increased to greater than € 680 million
• Swift implementation of the SHAPE programme
Net Profit expected to exceed € 130 million
• Excluding expected capital gains resulting from already announced
divestments
the next generation biopharma leader June 2009
Revenue expected to reach between € 3.1 - 3.3 billion
2009
Major milestones
29
Phase III top line results

Cimzia® in rheumatoid arthritis
U.S. approval & launch

Vimpat®
Launch in the U.S.

in epilepsy1
Epratuzumab in SLE
First Phase IIb results
Q3 2009
CDP7851 in bone loss disorders
Phase I to complete
H2 2009
1
Vimpat® has been designated as a Schedule V controlled
substance by U.S. regulators.
Adjunctive therapy in epilepsy
the next generation biopharma leader June 2009
Brivaracetam in epilepsy
2009
2 + 1 product launches so far
30
Launched in the U.S.
Adjunctive therapy in epilepsy
Launched in the U.S.
Toviaz®
Overactive bladder
Launched in the U.S., by Pfizer
the next generation biopharma leader June 2009
Rheumatoid arthritis
UCB
Our “road map”
31
Intense growth
Execution
Realise the commercial
potential of new products
Launch a new
generation of therapies
offering breakthrough
innovation to patients
with severe disease
• Launch
new products
• Invest in R&D
• SHAPE the organisation for the
future
• Prioritise products and markets
• Improve competitiveness and
profitability
2007
2010
... and beyond
the next generation biopharma leader June 2009
Breakthrough
32
the next generation biopharma leader June 2009
Appendix
Epilepsy
33
Excessive electrical activity in part or all of the brain resulting in
recurrent seizures
In most cases, there is no known cause for epilepsy
Can affect anyone regardless of age, gender or ethnicity
There is no known cure at this time but treatments are available to
reduce the frequency and severity of seizures
Prevalence:
≈ 6 million patients in 7 major markets1
Market size:
≈ € 3.2 billion in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008
IMS, 2008 - Sales in epilepsy only. Japan not included. U.S. =
Retail + Non-Fed hospitals
the next generation biopharma leader June 2009
The most common serious neurological disorder
Parkinson’s disease (PD)
34
Primary symptoms are tremor and trembling; stiffness of the limbs and
trunk; slowness of movement and impaired balance and coordination
No cure but a variety of medications provide relief from the symptoms
Prevalence:
≈ 3 million patients in 7 major markets1
Market size:
≈ € 790 million in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008
Sales in PD only - EU 5 only. Source: IMS, 2008
the next generation biopharma leader June 2009
CNS disorder, which is the result of the loss of dopamine-producing
brain cells
Restless legs syndrome (RLS)
35
The cause is unknown in most patients, but is suspected to be related
to lack of dopamine in the brain
It is a lifelong condition for which there is no cure
Few treatments available to treat moderate to severe RLS
Prevalence:
≈ 54 million patients in 7 major markets1
Market size:
≈ € 100 million in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008
Sales in RLS only. Source: IMS, EU5, Mat 11/08
the next generation biopharma leader June 2009
Neurological condition that is characterised by the irresistible urge to
move the legs
Diabetic neuropathic pain (DNP)
36
Several sub-types of neuropathic pain exist
Symptoms depend on the type of nerves affected and are often
associated with damage to the motor nerve such as muscle weakness,
cramps, and spasms
Very difficult to treat with only some 40-60% of patients achieving
partial relief
Prevalence:
≈ 10 million patients in 7 major markets1
Market size:
≈ € 390 million in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008
Decision Resources – Neuropathic Pain – April 2007
the next generation biopharma leader June 2009
Pain associated with a functional abnormality of the nervous system
Multiple sclerosis (MS)
37
Affects the ability of nerve cells in the brain and spinal cord to
communicate with each other
Cause not known and affects women more than men
No cure but medicines to slow it down, help control symptoms, prevent
new attacks, and prevent disability are available
Prevalence:
≈ 536 000 patients in 7 major markets1
Market size:
≈ € 4.3 billion in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources – 2008
Decision Resources – Pharmacor: Multiple Sclerosis – June 2008
the next generation biopharma leader June 2009
Chronic, inflammatory, demyelinating disease that affects the central
nervous system (CNS)
Crohn’s disease (CD)
38
Also referred to as Inflammatory Bowel Disease (IBD)
The cause is not known
Chronic condition, which means you have for life
The disease tends to fluctuate between periods of remission and relapse
There is no known cure for CD but treatments can help reduce
symptoms
Prevalence:
≈ 0.9 million patients in 7 major markets1
Market size:
≈ € 0.9 billion in 7 major markets2
1
2
PatientBase, Decision Resources – 2008
Datamonitor - Autoimmune Overview Forecast: Crohn’s Disease December 2007
the next generation biopharma leader June 2009
Autoimmune disease that causes chronic inflammation of the GI tract
Rheumatoid arthritis (RA)
39
Debilitating systemic condition
The cause of rheumatoid arthritis is not known
Symptoms come and go, depending on the degree of tissue
inflammation
There is no known cure for RA but treatments can reduce joint
inflammation and pain, maximize joint function, and prevent joint
destruction and deformity
Prevalence:
≈ 5 million patients in 7 major markets1
Market size:
≈ € 5.8 billion in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources – 2008
Decision Resources – Pharmacor: Rheumatoid Arthritis– June
2008
the next generation biopharma leader June 2009
Autoimmune disease that causes chronic and progressive inflammation
of the joints
Bone loss disorders
40
High associated morbidity and loss of daily independence caused by
disease
Treatments available for osteoporosis but significant need to improve
the quality of bone restored
Prevalence:
≈ 64 million patients in 7 major markets1
Market size:
≈ € 5.7 billion in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008 – Osteoporosis
Datamonitor – Commercial Insight :Osteoporosis – June 2007
the next generation biopharma leader June 2009
Reduction of bone mass (density) or presence of a fragility fracture
Systemic Lupus Erythematosus (SLE)
41
The word "systemic" means the disease can affect many parts of the body
The cause is not known (usually first affects people between the ages of
15 and 45 years)
The symptoms may be mild or serious, most common ones include
extreme fatigue, painful or swollen joints (arthritis), unexplained fever
and skin rashes
There is no known cure for SLE but it can be effectively treated with
drugs, and most people with the disease can lead active, healthy lives
Prevalence:
≈ 0.6 million patients in 7 major markets1
Market size:
≈ € 670 million in 7 major markets2 (2007)
1
2
PatientBase, Decision Resources - 2008
Datamonitor, IMS data taking into account off-label sales: both
minimum and maximum sales - Mar08
the next generation biopharma leader June 2009
Autoimmune disease that causes inflammation and damage to various
body tissues
Leading products compensate for Zyrtec® decline
42
Leading products
Keppra®
2008
YTD Change
Actual1
CER2
1 266
23%
30%
Zyrtec® (incl. D/Cirrus®)
249
-49%
-50%
Xyzal® 3
173
3%
4%
Tussionex™
147
29%
38%
Nootropil®
93
-8%
-7%
New products
Neupro®
58
12%
16%
Cimzia®
10
-
-
Vimpat®
2
-
-
3 027
-5%
-2%
Total net sales
1
2
3
the next generation biopharma leader June 2009
€ million
Actual: change from previous year unadjusted for foreign currency impact
CER: change from previous year adjusted for constant exchange rates
Excluding Xyzal® U.S. revenue to UCB of € 39 million from profit-sharing with
sanofi-aventis
2008 net sales
Geography
43
2007 net sales
€ 3 027 million
€ 3 188 million
Rest of
World
13%
North
America
40%
*
Rest of
World
12%
Europe
42%
Europe
47%
North
America
46%
the next generation biopharma leader June 2009
2008 net sales
2008 net sales
Therapy area
44
2007 net sales
€ 3 027 million
€ 3 188 million
Other
39%
CNS
47%
Immunology &
allergy
14%
*
Other
42%
CNS
37%
Immunology
and
allergy
21%
the next generation biopharma leader June 2009
2008 net sales
Employees
Geography - 2008
45
11 292
16%
20%
21%
13%
9%
21%
*
Belgium
Germany
U.K.
U.S.
Rest of EU
Emerging Markets
the next generation biopharma leader June 2009
Total number of employees
2009
Corporate financial calendar
46
Interim update (nine months report)
31 July
22 October
the next generation biopharma leader June 2009
2009 half-year results
Your Investor Relations team
47
• Phone +32 2 559 9414
• E-mail: [email protected]
Richard Simpson, Senior Director Investor Relations
• Phone: +32 2 559 9494
• E-mail: [email protected]
Michael Tuck-Sherman, Investor Relations Manager
• Phone: +32 2 559 9712
• E-mail: [email protected]
Isabelle Ghellynck, Investor Relations Project Manager
• Phone: +32 2 559 9588
• E-mail: [email protected]
the next generation biopharma leader June 2009
Antje Witte, Vice President Corporate Communications & Investor Relations